Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2021-04-15 Report Publication Anno…
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Terms of availability of a registration document or its updates
Report Publication Announcement Classification · 1% confidence The document explicitly states: "Ipsen publishes its 2020 Universal Registration Document" and details that this document was filed with the French regulator (AMF). A Universal Registration Document (URD) in the European context is a comprehensive annual filing that often incorporates the Annual Financial Report and Corporate Governance Report, similar in scope to a US 10-K, but it is a distinct regulatory filing type. Since the document is an announcement *of* the publication of this comprehensive annual document, and it is not the full 10-K itself, the most appropriate classification is Report Publication Announcement (RPA). If the text were the URD itself, it would likely map to 10-K or AR, but as a press release announcing its availability, RPA fits best, especially given the short length relative to a full annual report.
2021-04-15 English
Modalités de mise à disposition de document de référence ou de ses actualisations
Audit Report / Information Classification · 1% confidence The document is titled "Ipsen publie son Document d'enregistrement universel 2020" (Ipsen publishes its 2020 Universal Registration Document). The Universal Registration Document (Document d'enregistrement universel) in the French regulatory context typically contains the Annual Report (Rapport Financier Annuel) and the Corporate Governance Report (Rapport du Conseil d'administration sur la gouvernance d'entreprise), as explicitly stated in the text. While the content is an announcement about the filing, the filing itself is the comprehensive annual disclosure document. In the provided schema, the closest equivalent to a comprehensive annual report containing financial and governance details is the '10-K' (Annual Report). However, since this is a French filing (AMF) and the document explicitly states it *is* the Universal Registration Document which *contains* the Annual Report, it functions as the primary annual disclosure. Given the options, '10-K' is the best fit for the comprehensive annual filing, although 'RPA' (Report Publication Announcement) is also plausible as this is the announcement itself. Since the document is quite long (7671 chars) and details the contents of the filing (Annual Report + Governance Report), classifying it as the primary annual filing type ('10-K') is more accurate than classifying it as a mere announcement ('RPA'), especially since the '10-K' definition covers the 'Official yearly report covering company activity and full financial performance,' which the Universal Registration Document serves as. FY 2020
2021-04-15 French
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Share Issue/Capital Change Classification · 1% confidence The document is titled "Monthly information relative to the total number of voting rights and shares composing the share capital" and provides a table detailing the total number of shares and voting rights as of March 31, 2021. This type of regular disclosure regarding the capital structure and voting rights, often mandated by local financial authorities (like the AMF in France, mentioned here), is a specific regulatory disclosure. It is not a full annual report (10-K), an earnings release (ER), or a dividend announcement (DIV). It most closely aligns with a specific regulatory filing concerning share capital or voting rights updates. Given the options, this specific disclosure about the total number of voting rights and shares, which is a recurring regulatory requirement, fits best under the general 'Regulatory Filings' category (RNS) as there is no specific code for 'Monthly Voting Rights Disclosure'. However, since it is a direct disclosure of capital structure components, it is a specific regulatory filing.
2021-04-09 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de Commerce and AMF General Regulation) and provides a table detailing the total number of shares and voting rights as of March 31, 2021. This type of regular disclosure concerning the total share capital and voting rights structure is a specific regulatory filing requirement, often related to capital structure changes or mandatory periodic updates. While it relates to capital, it is not a fundraising announcement (CAP) or a general share issue (SHA). It is a mandatory periodic disclosure about the capital structure and voting rights. Given the options, this most closely aligns with a specific regulatory disclosure concerning capital structure, but since there isn't a perfect fit for a 'Monthly Voting Rights Disclosure', I must evaluate the closest options. It is not an AGM, 10-K, ER, or IR. It details the composition of the capital and voting rights, which is a fundamental aspect of share structure. The closest fit among the provided codes that deals with capital structure reporting, although not perfectly named, is 'SHA' (Share Issue/Capital Change) or potentially 'RNS' (Regulatory Filings) as a fallback. However, since it is a specific, recurring report on the total number of shares and voting rights, it is a distinct regulatory filing. In many jurisdictions, this type of filing is often categorized under general capital structure disclosures. Given the options, and recognizing this is a mandatory disclosure about the total number of shares and voting rights, it is a specific capital structure notification. If 'SHA' is interpreted broadly as any official report on the share count, it fits. If not, 'RNS' is the fallback. Since it is a formal, periodic report on the capital base, I will classify it as a specific regulatory filing that impacts share structure reporting, leaning towards 'SHA' as the most relevant category dealing with the number of shares, or 'RNS' if it's considered a general regulatory update. Given the highly specific nature of the other codes, and the lack of a 'Voting Rights Disclosure' code, 'RNS' (Regulatory Filings - fallback) is the safest classification for a mandatory, non-standard report type, although it is highly specific to capital structure. Let's re-evaluate: This is a mandatory disclosure of the total number of shares and voting rights, which is a key component of capital structure reporting. It is not a transaction (POS) or a change in ownership threshold (MRQ). It is a statement of the current state of the capital base. I will classify it as RNS as it is a specific regulatory filing that doesn't fit the other defined categories perfectly, especially since it is a monthly update rather than an annual or quarterly financial report (10-K/IR).
2021-04-09 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated March 31, 2021, announcing that the European Commission (CE) has approved the combination of Cabometyx® and Opdivo® for advanced renal cell carcinoma (RCC). It details clinical trial results (CheckMate 9ER), efficacy data (PFS, OS), and quotes company executives and physicians. This type of announcement, focusing on a significant regulatory milestone (approval) and summarizing clinical data, is characteristic of an Earnings Release (ER) or a general corporate/regulatory update. Since it is a formal announcement of a major event (regulatory approval) rather than a comprehensive financial report (10-K or IR) or a transcript (CT), it fits best under the 'Earnings Release' category, which often encompasses major corporate news releases regarding product milestones, even if not strictly quarterly earnings. Given the context of pharmaceutical news, 'ER' is the most appropriate fit for a major product approval announcement press release.
2021-03-31 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release from Ipsen announcing that the European Commission has approved Cabometyx® in combination with Opdivo® for a specific medical condition (advanced renal cell carcinoma). It details the clinical trial data (CheckMate -9ER) that supported this approval, mentions publication in the NEJM, and provides context about the drug and the disease. This type of announcement, focusing on a major regulatory milestone (approval) and summarizing the underlying clinical/scientific data, is characteristic of an Earnings Release (ER) or a general corporate/product update. Since it is not a full annual report (10-K), a quarterly report (IR), a transcript (CT), or a specific financial filing like a proxy (DEF 14A), and it is announcing a significant business/regulatory event, it fits best as an Earnings Release (ER) which often includes major operational news alongside financial highlights, or potentially a Regulatory Filing (RNS) if it were purely a notification. Given the detailed summary of the approval and trial results, it functions as a major business update, aligning closely with the scope of an ER, even if it's not strictly quarterly earnings. However, looking at the definitions, it is a specific announcement about a product/regulatory event, not a general earnings report. It is not a proxy statement (DEF 14A) or a management discussion (MDA). Since it is a major corporate announcement regarding a product approval based on clinical data, and it is not a short announcement pointing to an attached report (RPA), it is best classified as a general corporate announcement. Given the options, 'Regulatory Filings' (RNS) serves as the best fallback for significant, non-standard corporate news that doesn't fit the financial reporting codes (10-K, IR, ER). However, the content strongly suggests a major business development announcement. If we must choose between ER (Earnings Release - initial announcement of results) and RNS (Regulatory Filings - general announcement), this is a regulatory/product success announcement. In many databases, major product approvals are categorized under general regulatory news or press releases. I will classify it as RNS as it is a significant regulatory/product announcement that doesn't fit the specific financial report types.
2021-03-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.